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Gangliosides, sialic acid-bearing glycosphingolipids, are expressed at high abundance and complex-
ity in the brain. Altered ganglioside expression results in neural disorders, including seizures and
axon degeneration. Brain gangliosides function, in part, by interacting with a ganglioside-binding
lectin, myelin-associated glycoprotein (MAG). MAG, on the innermost wrap of the myelin sheath,
binds to gangliosides GD1a and GT1b on axons. MAG–ganglioside binding ensures optimal axon–
myelin cell–cell interactions, enhances long-term axon–myelin stability and inhibits axon out-
growth after injury. Knowledge of the molecular interactions of brain gangliosides may improve
understanding of axon–myelin stability and provide opportunities to enhance recovery after nerve
injury.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction Myelin, the multilamellar membrane that wraps many nerveGangliosides, sialic acid-bearing glycosphingolipids expressed
on all vertebrate tissues, are found in relatively high abundance
and structural complexity in the brain, where they represent 1%
of total brain lipids [1,2]. The ceramide lipid moieties of ganglio-
sides are embedded in the outer leaﬂet of the plasma membrane,
and their complex glycans extend into the extracellular space [3].
As major cell surface structural determinants, gangliosides are
positioned to interact laterally with other molecules in their own
membranes and with molecules on apposing cell membranes
[4,5]. Lateral (cis) molecular interactions in the plane of the mem-
brane result in ganglioside-mediated regulation of membrane pro-
teins (such as receptor kinases) whereas interactions with proteins
on apposing membranes (trans) result in ganglioside-mediated
cell–cell recognition. When trans and cis interactions are com-
bined, ganglioside-mediated cell–cell recognition can result in
changes in cell signaling and cell physiology. One cell–cell recogni-
tion system in which gangliosides have been implicated is that be-
tween myelin and axons.chemical Societies. Published by E
AG, myelin-associated glyco-
n; P4, 1-phenyl-2-hexadec-
lecular Sciences, The Johns
timore, MD 21205, USA. Fax:axons in vertebrates, is required for rapid nerve conductance,
allowing slender axons to carry electrical signals over long dis-
tances [6]. Myelination of axons by Schwann cells (in the periphe-
ral nervous system, PNS) or oligodendrocytes (in the central
nervous system, CNS) results in segmental stretches of myelin
(internodes) separated by narrow gaps, the nodes of Ranvier
(Fig. 1). These gaps are highly structured; they are bordered by
loops of myelin that form a seal surrounding the circumference
of the underlying axon [6]. Myelination not only insulates axon
membranes in internodes, but also regulates the lateral distribu-
tion of membrane molecules at nodes of Ranvier. Voltage-gated so-
dium channels are clustered at the nodes, allowing depolarizing
currents to jump from node-to-node, the mechanism for rapid ‘‘sal-
tatory” conduction of an action potential across long distances. The
loops of myelin that seal the edge of each node deﬁne the paranod-
al region, which is characterized by its own set of molecules and
tight membrane-to-membrane adhesion between the axon and
myelin. A specialized segment of axon adjacent to the paranode
(further from the node), termed the juxtaparanode, is character-
ized by the presence of voltage-gated potassium channels that help
return the membrane to its resting state after depolarization. To-
gether, this complex of membrane molecules supports highly efﬁ-
cient and rapid action potential propagation.
In addition to insulating axons and regulating molecular distri-
butions at nodes of Ranvier, myelin nurtures the axons it en-
sheathes [7]. When myelin is lost (e.g. by disease), axons suffer.
The progressive long-term deﬁcits of ‘‘pure demyelinating”lsevier B.V. All rights reserved.
Fig. 1. Myelin and nodes of Ranvier in the CNS. An oligodendrocyte (blue) ensheathing a neuronal axon (yellow) is shown. Axon ensheathment occurs in stretches along the
axon (myelin internodes) that are interrupted by specialized gaps, nodes of Ranvier. The ultrastructural insert shows characteristic paranodal myelin loops adhering ﬁrmly to
an axon at the edge of the node. Reproduced with permission [56].
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chronic and irreversible secondary loss of axons. Studies of human
disease and animal models of disease indicate that myelin acts as a
stabilizing factor required for long-term survival of myelinated
axons.
Whereas axon stability is required for healthy nervous system
function, stabilization signals may be counterproductive after in-
jury. The injured CNS is a highly inhibitory environment for axon
regeneration, in part because molecules on residual myelin at the
injury site speciﬁcally signal axons to halt regrowth [8]. Under-
standing myelin-mediated ‘‘stop” signals and the molecular path-
ways responsible provides new therapeutic targets to enhance
recovery from CNS trauma, such as spinal cord injury [9].
Sets of complementary molecules on apposing axon and myelin
surfaces are essential for accurate and efﬁcient myelination, long-
term axon stability, and regulation of axon outgrowth. Biochemi-
cal, cell biological and genetic data indicate that gangliosides (on
the axon surface) and a complementary binding protein, myelin-
associated glycoprotein (MAG, on myelin) contribute to these func-
tions [10].
2. Brain gangliosides
Gangliosides are glycosphingolipids that carry one or more sia-
lic acid residue(s) in their oligosaccharide structure [3]. In the
brain, ganglioside structures and expression levels are conserved
among mammals [1], with four gangliosides – GM1, GD1a, GD1b
and GT1b – making up the vast majority (96% of brain gangliosides
in man, see Fig. 2 for ganglioside structures). The ceramide lipid
moiety of brain gangliosides is most often comprised of an 18- or
20-carbon sphingosine and a saturated fatty acid amide, such as
C18:0. The biophysical properties of the ceramide moiety result
in ganglioside clustering in the plane of the membrane [3], a topic
discussed elsewhere in this Special Issue.Ganglioside biosynthesis is step-wise [11], starting with trans-
fer of glucose to ceramide (Fig. 2). Subsequent additions of galact-
ose, sialic acid, and N-acetylgalactosamine from their nucleotide
sugar donors to the growing saccharide chain generate the pen-
ta-, hexa- and heptasaccharide glycans of the major brain ganglio-
sides. Simpler ganglioside structures (GM3 and GD3, see Fig. 2)
predominate early in development with the mature major brain
gangliosides emerging during the third trimester in rodents [12].
In humans, a sharp increase in brain ganglioside expression begins
in the third trimester and extends through the ﬁrst two postnatal
years [13], the same period in which myelination is most active
[14].
3. Brain gangliosides are receptors for myelin-associated
glycoprotein (MAG)
Vertebrate cell surfaces, including neurons and their axons, are
endowed with a rich and diverse glycan coat, the glycocalyx [15].
Cell surface glycan structures often act as receptors for comple-
mentary glycan binding proteins, lectins, expressed on apposing
cell surfaces. Lectin–glycan binding mediates cell–cell recognition
and regulates cell physiology. Several families of lectins, compris-
ing over 100 different proteins with varied glycan binding speciﬁc-
ities, are coded in the human genome.
Members of one lectin family, the siglecs, bind with high spec-
iﬁcity to glycans terminated with sialic acids [16]. Sialic acids are
the most abundant terminal sugar in mammalian glycans, and ex-
ist in diverse groupings with other sugars [17]. Siglec family mem-
bers take advantage of sialoglycan structural diversity; some bind
speciﬁcally to a2-6-linked sialic acids, and others to a2-3- or a2-8-
linked sialic acids. In the siglec family, only one member, myelin-
associated glycoprotein (MAG, Siglec-4) is expressed in the brain,
and appears to be designed to bind to the major brain gangliosides
GD1a and GT1b.
Fig. 2. Ganglioside structures and their biosynthesis. Top: The structure of GD1a is shown with the MAG-binding determinant (NeuAc a2-3 Gal b1-3 GalNAc) shaded. Bottom:
Biosynthetic pathways to the major brain gangliosides. The MAG-binding determinant is shaded, and the glycosyltransferases discussed in the text, B4galnt1, St8sia1, and
St3gal5 are shown. St3gal5-null mice lack normal major brain gangliosides, but instead synthesize an equivalent amount of the otherwise rare gangliosides cisGM1 (GM1b)
and GD1a, both of which carry the MAG-binding determinant. Reproduced with permission [10].
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linked sialic acid, and has high afﬁnity for glycans that carry the
terminal sequence ‘‘NeuAc a2-3 Gal b1-3 GalNAc” [18]. On nerve
cells and axons this terminus is most abundantly expressed on
gangliosides GD1a and GT1b [19]. In vitro, MAG binds avidly to
GD1a and GT1b, but not to closely related gangliosides (e.g. GM1
and GD1b), which lack the ‘‘NeuAc a2-3 Gal b1-3 GalNAc” termi-
nus [20,21]. Altering the hydroxyls, the N-acyl group or the carbox-
ylic acid on the terminal sialic acid of a ganglioside eliminates MAG
binding, indicating that MAG is highly evolved to engage sialogly-
cans with high speciﬁcity [22]. The binding data led to the hypoth-
esis that MAG, on myelin, functions in vivo by binding to
gangliosides GD1a and/or GT1b expressed on the axon surface
[20]. Genetic studies are consistent with this hypothesis.
4. Genetic studies implicate gangliosides in axon–myelin
interactions
Gangliosides are biosynthesized step-wise by a series of speciﬁc
glycosyltransferases (Fig. 2). The functions of gangliosides can be
inferred by studying the phenotypes of mice engineered to lack
one or more of these enzymes [23,24]. A particularly revealing mu-
tant lacks expression of the N-acetylgalactosaminyltransferase re-
quired to initiate the ‘‘NeuAc a2-3 Gal b1-3 GalNAc” terminus on
gangliosides [25–27]. When the gene responsible, B4galnt1 (previ-
ously called Galgt1 or GM2/GD2 synthase) is disrupted, none of
the major brain gangliosides are expressed. The total brain gangli-
oside concentration remains the same as in wild-type mice, butwith the simple gangliosides GM3 and GD3 accumulating behind
the biosynthetic block [28]. Since GD3 does not support MAG
binding, and GM3 supports relatively poor MAG binding [21], the
expectation was that B4galnt1-null mice would have impaired
axon–myelin interactions. This is what was found [27]. Although
B4galnt1-null mice are born in Mendelian frequencies and survive
to adulthood, they display progressive neuropathy characteristic
of a loss of axon–myelin stability. By the time they are one year
of age, they have signiﬁcantly impaired hindlimb mobility. A com-
parison of B4galnt1-null, MAG-null and B4galnt1/MAG double null
mice reveals striking similarities in their phenotypes [29]. They
all display signiﬁcant axon degeneration in the CNS and PNS, re-
duced axon caliber, reduced axon neuroﬁlament spacing, andmotor
behavioral deﬁcits consistent with neuropathy, such as impaired
motor coordination and poor hindlimb reﬂexes. The phenotypic
similarity between B4galnt1-null, MAG-null and double null mice
is consistent with the hypothesis that MAG and gangliosides partic-
ipate in the same pathway, enhancing axon–myelin stability. The
intracellular signaling pathways downstream of MAG-ganglioside
binding that lead to enhanced stability have not been established.
In addition to supporting long-term axon stability, complex
gangliosides contribute to appropriate axon–myelin interactions
at nodes of Ranvier [30]. Whereas wild-type nodes are character-
ized by well-organized paranodal loops with characteristic
‘‘transverse bands” mediating axon–myelin attachments, B4gal-
nt1-null mice often display poorly structured paranodal loops
that fail to attach to the axon or that attach but lack transverse
bands. Immunohistochemical localization of sodium and potas-
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regulate nodal structure. In B4galnt1-null mice, sodium channels,
normally restricted to narrow band at the node, are broadened.
Potassium channels, normally spaced away from the node by
the paranode, also are broadened to populate the paranode. It
is likely that these structural and molecular deﬁcits at nodes
of Ranvier underlie the reduced motor nerve conduction velocity
measured in electrophysiological studies of B4galnt1-null mice
[25,30].
The phenotype of B4galnt1-null mice revealed that complex
gangliosides are required for axon–myelin long-term stability.
The data are consistent with the hypothesis that the observed neu-
ronal deﬁcits are due to the loss of MAG interaction with its axonal
receptors, GD1a and GT1b. However, loss of the B4galnt1 gene
product, GM2/GD2 synthase, results in loss of all complex ganglio-
sides, not just those that interact with MAG [25,26,28]. To infer
which gangliosides are responsible for axon–myelin stability, it is
instructive to consider mice with mutations in genes coding other
enzymes in the ganglioside biosynthetic pathway (see Fig. 2)
[23,24].
B4galnt1-null mice express about the same total brain ganglio-
side concentration as wild-type mice, building up the simpler spe-
cies behind the metabolic block [28]. Likewise, except for mice
with no brain gangliosides (see below), mice with disruptions in
other ganglioside biosynthetic genes express about the same total
concentration of brain gangliosides, building up gangliosides be-
hind each genetic block [31]. Thus, St8sia1-null (GD3 synthase-
deﬁcient) mice build up GM1 and GD1a in the absence of ‘‘b-series”
gangliosides. These mice express ample amounts of the MAG-bind-
ing ganglioside GD1a, and do not have overt axon–myelin deﬁcits.
St3gal5-null (GM3 synthase-deﬁcient) mice, which might be ex-
pected to lack all brain gangliosides, instead express the same total
brain ganglioside concentration as wild-type mice, but in the form
of the normally rare gangliosides cisGM1 (GM1b) and GD1a (see
pathways, Fig. 2) [32]. These mice do not have overt axon–myelin
deﬁcits. Notably, GD1a, which is amply expressed in St3gal5-null
mice [32], supports avid MAG-binding. To block all ‘‘ganglio-series”
brain ganglioside biosynthesis, Yamashita et al. engineered
St3gal5/B4galnt1 double null mice (see Fig. 2) [33]. These mice fail
to express signiﬁcant amounts of brain gangliosides and demon-
strate early axonal degeneration and severely perturbed axon–
myelin interactions. These studies, taken together, are consistent
with a role for MAG-binding gangliosides (GD1a and GT1b) in
axon–myelin stability.
Human genetic deﬁcits in the enzymes that biosynthesize major
brain gangliosides are exceedingly rare. Nevertheless, a small clade
of individuals was identiﬁed with a disrupted St3gal5 gene (see
Fig. 2) [34]. The affected children all displayed seizures before they
were one year old. This was followed by diffuse brain atrophy, are-
ﬂexia, and developmental regression. Seizure activity has been ob-
served in ganglioside-deﬁcient mice as well [31]. Although
additional data will be needed to correlate ganglioside structure
to ganglioside function in this rare human disorder, a critical role
of gangliosides in human brain function has been established.Fig. 3. Dual MAG receptor model. MAG is envisioned as interacting independently
with gangliosides (GD1a or GT1b, MAG-binding determinant highlighted) and with
NgR’s (NgR1 or NgR2). In each pathway, MAG engagement results in transmem-
brane signals. For example, NgR1 interacts with transmembrane signaling mole-
cules p75NTR and Lingo-1 to transduce a signal that results in RhoA activation and
inhibition of axon outgrowth. Gangliosides may signal via some of the same
components, or via yet undeﬁned components as shown, to activate RhoA,
modulate axon and node of Ranvier structures, and stabilize axons. Additional
modulating factors (cAMP, calcium, PKC) and potential pathway crosstalk are not
shown (see [8]). Reproduced with permission [10].5. Gangliosides as receptors for MAG inhibition of axon
outgrowth
The injured adult vertebrate central nervous system is an inhib-
itory environment for axon regeneration, resulting in poor recov-
ery after, for example, spinal cord injury [8,35]. In part, this is
due to speciﬁc ‘‘axon regeneration inhibitors” (ARIs) that accumu-
late at injury sites, including the protein molecules MAG, Nogo, and
oligodendrocyte-myelin glycoprotein (OMgp) on residual myelin
(Fig. 3) and chondroitin sulfate proteoglycans on reactive astro-cytes. In each case, ARIs bind to receptors on axons, signaling them
to halt regeneration. Since MAG binds with high speciﬁcity to the
major axon gangliosides GD1a and GT1b, we proposed that MAG
engagement of these gangliosides is responsible for inhibiting axon
regeneration [20]. Several lines of data support this hypothesis
[9,36–38]. Although inhibition is multifaceted and complex,
MAG-ganglioside binding appears to be one pathway leading to
axon outgrowth inhibition.
Evidence for ganglioside involvement in axon outgrowth inhibi-
tion came from in vitro experiments using primary nerve cells iso-
lated from newborn rats and mice. Binding of an molecularly
expressed form of MAG (MAG-Fc) to some types of nerve cells
was completely reversed by pretreatment of the nerve cells with
sialidase [18,39]. In functional studies, inhibition of axon outgrowth
induced by MAG was reversed by sialidase, by the ganglioside
biosynthetic inhibitor P4 (1-phenyl-2-hexadecanoylamino-3-pyrr-
olidino-1-propanol), and by antibodies to GD1a or GT1b [36,37].
Furthermore, nerve cells isolated from B4galnt1-null mice, which
lack complex gangliosides including GD1a and GT1b, were less
responsive to MAG-mediated inhibition [37]. Together, these data
implicate gangliosides as functional MAG receptors responsible
for axon outgrowth inhibition. It has been proposed that MAG
engages and clusters GD1a or GT1b at the axon surface, halting
axon outgrowth. In support of this concept, antibody-mediated
crosslinking of gangliosides GD1a or GT1b at the nerve cell surface
mimicked MAG inhibition, and the same ultimate downstream
intracellular signaling pathway, activation of the small GTPase
RhoA, was found to be responsible for axon outgrowth inhibition
by both MAG and anti-ganglioside antibodies [36,37,40,41].
Although gangliosides are strongly implicated asMAG receptors,
and can mediate axon outgrowth inhibition, there are other MAG
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[40,43].WhereasMAG inhibition of axon outgrowth from cerebellar
granule and hippocampal neurons is largely via gangliosides, as evi-
denced by reversal of inhibition by sialidase or P4,MAG inhibition of
retinal and dorsal root ganglion axon outgrowth is largely resistant
to these treatments. Neurons that did not depend on gangliosides
to respond to MAG, appeared to respond via a second class of MAG
receptors, the glycophosphatidylinositol (GPI) linked NgR family of
proteins. Some data indicate that ganglioside-mediated and NgR-
mediated inhibition of axon regeneration are independent [40].
Other data suggest that NgR and gangliosides, both of which parti-
tion in membrane rafts [44], cooperate to signal axon outgrowth
inhibition [41]. Recently, additional MAG receptors were reported
[42,45]. Sorting out which receptors regulate which nerve cell re-
sponses in different circumstances will be important in considering
potential therapeutic implications of gangliosides as regulators of
axon regeneration after injury.6. Modulating gangliosides to enhance axon outgrowth after
injury
If gangliosides act as functionalMAG receptorsmediating inhibi-
tion of axon outgrowth after nervous system injury, would blocking
ormodifying gangliosides enhance recovery? Evidence from in vitro
studies suggests that recovery in response to ganglioside modiﬁca-
tion would depend on which nerve cell axons were injured [40,43].
Furthermore, given the number and complexity of axon outgrowth
inhibitorymoleculesandpathways (Fig. 3), gangliosidemodiﬁcation
might have to be combinedwith other anti-ARI therapies to be effec-
tive [8,9]. Despite these caveats, evidence in support of ganglioside
modiﬁcation therapy comes from a study in which sialidase, one of
the most robust in vitro treatments to reverse MAG-mediated axon
outgrowth inhibition, enhances motor axon outgrowth when deliv-
ered to a nerve injury in vivo [46].
Brachial plexus avulsion is an injury in which the nerves leading
to and from the arm are yanked out of the spinal cord, most com-
monly during a motor vehicle accident, leaving the arm completely
paralyzed [47]. To model this injury in rats, nerve roots at the
shoulder level were exposed and cut ﬂush where they entered/ex-
ited the spinal cord [46]. A nerve graft was inserted into the spinal
cord at the injury site in an attempt to coax motoneuron axons out
of the spinal cord. Sialidase was injected onto the insertion site
immediately after graft insertion, and then pumped onto the site
continually for 14 days thereafter. After 4 weeks, neurons that ex-
tended new axons from the spinal cord into the graft were labeled
by retrograde ﬂuorescent labeling and counted. The results were
striking. Without sialidase 170 axons exited the spinal cord into
the graft, whereas with sialidase treatment >400 spinal axons en-
tered the graft. The morphology of the labeled cells indicated that
the axons were from motor neurons. The number of axons exiting
the spinal cord and entering the graft in sialidase-treated animals
was signiﬁcant, with recovery of perhaps half of the number of mo-
tor axons that exit the spinal cord at that level in an uninjured rat.
Since sialidase cleaves sialic acid from sialoglycoproteins as
well as gangliosides (sialoglycolipids), it is not possible to ascribe
the enhanced spinal axon outgrowth to gangliosides per se. Fur-
thermore, sialidase treatment cleaves only the external sialic acids
from complex gangliosides, leaving an increased concentration of
the ganglioside GM1, which itself may affect axon outgrowth
[48–50]. Nevertheless, since GD1a and GT1b are major sialoglycans
of nerve tissue, and have been implicated in axon outgrowth con-
trol via their interaction with MAG, the data are consistent with a
role for these gangliosides in inhibiting axon outgrowth after
injury in vivo, and identify these gangliosides as potential thera-
peutic targets.If speciﬁc gangliosides are required for proper axon–myelin
architecture and long-term axon–myelin stability, how can their
destruction enhance recovery from injury? It is hoped that gangli-
oside-modifying treatments such as sialidase might be adminis-
tered during a critical period after injury to enhance plasticity
and encourage axon outgrowth. Thereafter, treatment would be
halted to allow expression of the normal assortment of major brain
gangliosides required for long-term axon–myelin health.7. Challenges and perspectives
Biochemical, cellular and genetic data (see above) conﬁrm that
complex brain gangliosides play important roles in the long-term
stability of axons and in the regulation of axon regeneration. We
infer that engaging GD1a or GT1b on the outer leaﬂet of the plas-
ma membrane generates transmembrane signals that result in
fundamental changes in the cytoskeleton that halt axon out-
growth and support axon survival and function. Since ganglio-
sides do not span the membrane, biochemical mechanisms
must exist to detect ganglioside engagement and convert binding
to transmembrane signals [4]. This may occur by altering direct
lateral associations of gangliosides with transmembrane signaling
molecules. Alternatively, gangliosides constitutively associate
with each other and certain other outer leaﬂet molecules to form
microdomains, also called lipid rafts. These rafts accumulate sig-
naling molecules on the inner leaﬂet, such as Src-family kinases.
Aggregating gangliosides on the outer membrane leaﬂet may alter
signaling molecule associations on the inner leaﬂet. There are
precedents for both direct and raft-mediated ganglioside sig-
naling.
Gangliosides can associate directly with transmembrane signal-
ing molecules and modulate their downstream signaling. For
example, insulin and EGF receptors associate laterally with gangli-
oside GM3, resulting in decreased tyrosine kinase activity in re-
sponse to insulin and EGF, respectively [32,51,52]. In contrast,
the activity of the TrkA neurotrophin receptor, which is responsible
for NGF-induced axon outgrowth, is enhanced by its association
with ganglioside GM1 [48].
More directly relevant to axon–myelin interactions, there is evi-
dence for the physical association of gangliosides with p75NTR [53]
and NgR1 [41], two transmembrane signaling molecules on axons
implied in axon outgrowth inhibition by MAG in some cell types.
However, ganglioside-mediated axon outgrowth inhibition (at
least in some neurons) is clearly independent of p75NTR and NgR
[40,43]. This does not exclude the potential role of ganglioside–
p75NTR or ganglioside–NgR associations in axon–myelin interac-
tions, but other mechanisms must also exist.
Engaging gangliosides on the outer leaﬂet of the plasma mem-
brane can regulate the activity of lipid-raft-associated signaling
molecules on the inner leaﬂet. For example, antibody-induced
crosslinking of GM3 on melanoma cells activates Src and RhoA
[54], and crosslinking GD3 on cerebellar neurons activates Lyn
[55]. In a ganglioside-mediated axon outgrowth study, the extra-
cellular matrix molecule laminin-1 was found to bind and cluster
GM1, resulting in recruitment of TrkA and b1 integrin to rafts
and activation of Lyn on the inner leaﬂet [50]. These data provide
a precedent for raft-mediated outside-in signaling initiated by gan-
glioside clustering.
The signaling molecules and mechanisms that are responsible
for converting MAG-ganglioside binding to enhanced axon–myelin
stability and axon outgrowth inhibition have not been fully de-
scribed. Given the above precedents, it is likely that clustering gan-
gliosides on the axon surface impacts transmembrane receptors,
lipid raft signaling molecules, or both. Identifying the speciﬁc
molecules and mechanisms involved may provide additional
1746 R.L. Schnaar / FEBS Letters 584 (2010) 1741–1747opportunities to enhance long-term axon stability and improve
axon regeneration after injury.
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